LAUSR.org creates dashboard-style pages of related content for over 1.5 million academic articles. Sign Up to like articles & get recommendations!

A phase 1 study to evaluate the safety, pharmacology, and feasibility of continuous infusion nelarabine in patients with relapsed and/or refractory lymphoid malignancies

Photo from wikipedia

Nelarabine is a purine nucleoside analogue prodrug approved for the treatment of relapsed and refractory T‐cell acute lymphoblastic leukemia (R/R T‐ALL) and lymphoblastic lymphoma (T‐LBL). Although effective in R/R T‐ALL,… Click to show full abstract

Nelarabine is a purine nucleoside analogue prodrug approved for the treatment of relapsed and refractory T‐cell acute lymphoblastic leukemia (R/R T‐ALL) and lymphoblastic lymphoma (T‐LBL). Although effective in R/R T‐ALL, significant neurotoxicity is dose‐limiting and such neurotoxicity associated with nucleoside analogues can be related to dosing schedule.

Keywords: pharmacology; study evaluate; relapsed refractory; evaluate safety; phase study; safety pharmacology

Journal Title: Cancer
Year Published: 2022

Link to full text (if available)


Share on Social Media:                               Sign Up to like & get
recommendations!

Related content

More Information              News              Social Media              Video              Recommended



                Click one of the above tabs to view related content.